未登录

H

Huma Dar

karolinska institutet

H指数:3

被引数:89

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

ER+ HER2−乳腺癌患者接受辅助他莫昔芬治疗获得长期获益与PR阳性的关系

International Journal of Cancer

IF4.7

2026-03-050

OAAI

Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial

孕酮受体（PR）在绝经前乳腺癌中的肿瘤内异质性：一项随机试验的二次分析

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2025-10-010

OAAI

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2024-12-040

PRE

Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

luminal A型和B型乳腺癌高危和低危绝经前及绝经后患者长期他莫昔芬的获益

ANNALS OF ONCOLOGY

IF65.4

2024-09-010

PRE

Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer

CANCER RESEARCH

IF16.6

2023-03-011

PRE

Long-Term Benefit from Adjuvant Tamoxifen in Luminal A and Luminal B Breast Cancer Patients

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Differential Long-Term Benefit from Adjuvant Tamoxifen Therapy in Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Premenopausal and Postmenopausal Breast Cancer Patients

CANCER RESEARCH

IF16.6

2023-03-010

PRE

20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials

ANNALS OF ONCOLOGY

IF65.4

2022-05-010

OA

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

JAMA NETWORK OPEN

IF9.7

2021-06-3019

OAAI

20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

ANNALS OF ONCOLOGY

IF65.4

2021-05-010

OA

25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

ANNALS OF ONCOLOGY

IF65.4

2021-05-010

OA

Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study

与其他癌症的女性幸存者相比，年轻和最近诊断的乳腺癌幸存者的生活质量较差: 一项横断面研究

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2016-08-1630

OAAI